NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Exwannabe,

Thanks for the clarification and thank you Sentiment, Flipper, doingmybest and Doc logic for your help.
I believe it is clear now and I found more evidence for your explanation in another paper from the EMA.

Exwannabe or someone else, maybe you can help me with this:

This year, in Europe, two Marketing Authorisation Applications (MAA) for ATMP's are submitted.

One between 16 March 2018 and 18 April 2018.

https://www.ema.europa.eu/documents/committee-report/cat-monthly-report-application-procedures-guidelines-related-documents-advanced-therapies-march-2018_en.pdf
https://www.ema.europa.eu/documents/committee-report/cat-monthly-report-application-procedures-guidelines-related-documents-advanced-therapies-april-2018_en.pdf

A second between 14 September 2018 and 10 October 2018.

https://www.ema.europa.eu/documents/committee-report/cat-monthly-report-application-procedures-guidelines-related-documents-advanced-therapies-september_en-5.pdf
https://www.ema.europa.eu/documents/committee-report/cat-monthly-report-application-procedures-guidelines-related-documents-advanced-therapies-october_en-5.pdf

Is there a way to find out if one of the two MAAs is for dcvax-l???